These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23114871)

  • 1. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
    Hu J; Deng H; Friedman EA
    Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirk/dyrk1B Kinase in Ovarian Cancer.
    Friedman E
    Int J Mol Sci; 2013 Mar; 14(3):5560-75. PubMed ID: 23528858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
    Ewton DZ; Hu J; Vilenchik M; Deng X; Luk KC; Polonskaia A; Hoffman AF; Zipf K; Boylan JF; Friedman EA
    Mol Cancer Ther; 2011 Nov; 10(11):2104-14. PubMed ID: 21878655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2.
    Hu J; Nakhla H; Friedman E
    Int J Cancer; 2011 Jul; 129(2):307-18. PubMed ID: 20857490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.
    Deng X; Ewton DZ; Friedman E
    Cancer Res; 2009 Apr; 69(8):3317-24. PubMed ID: 19351855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirk regulates the exit of colon cancer cells from quiescence.
    Jin K; Ewton DZ; Park S; Hu J; Friedman E
    J Biol Chem; 2009 Aug; 284(34):22916-25. PubMed ID: 19542220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy.
    Becker W
    FEBS J; 2018 Apr; 285(7):1203-1211. PubMed ID: 29193696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.
    Gao J; Yang X; Yin P; Hu W; Liao H; Miao Z; Pan C; Li N
    Int J Oncol; 2012 Apr; 40(4):1203-9. PubMed ID: 22159921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirk kinase inhibition targets ovarian cancer ascites.
    Deng X; Hu J; Cunningham MJ; Friedman E
    Genes Cancer; 2014 May; 5(5-6):201-11. PubMed ID: 25061503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirk/dyrk1B kinase is upregulated following inhibition of mTOR.
    Deng X; Hu J; Ewton DZ; Friedman E
    Carcinogenesis; 2014 Sep; 35(9):1968-76. PubMed ID: 24590896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells.
    Gao J; Zhao Y; Lv Y; Chen Y; Wei B; Tian J; Yang Z; Kong F; Pang J; Liu J; Shi H
    Cancer Cell Int; 2013 Jan; 13(1):2. PubMed ID: 23311607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells.
    Hu J; Friedman E
    Genes Cancer; 2010 Aug; 1(8):803-811. PubMed ID: 21113238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase.
    Deng X; Mercer SE; Shah S; Ewton DZ; Friedman E
    J Biol Chem; 2004 May; 279(21):22498-504. PubMed ID: 15010468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirk/Dyrk1B in cancer.
    Friedman E
    J Cell Biochem; 2007 Oct; 102(2):274-9. PubMed ID: 17583556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
    Massey AJ; Benwell K; Burbridge M; Kotschy A; Walmsley DL
    J Cell Mol Med; 2021 Nov; 25(22):10650-10662. PubMed ID: 34708541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy.
    Kokkorakis N; Zouridakis M; Gaitanou M
    Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.
    Gao J; Zheng Z; Rawal B; Schell MJ; Bepler G; Haura EB
    Cancer Biol Ther; 2009 Sep; 8(17):1671-9. PubMed ID: 19633423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid turnover of cell-cycle regulators found in Mirk/dyrk1B transfectants.
    Ewton DZ; Lee K; Deng X; Lim S; Friedman E
    Int J Cancer; 2003 Jan; 103(1):21-8. PubMed ID: 12455049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells.
    Deng X; Friedman E
    Genes Cancer; 2014 Sep; 5(9-10):337-47. PubMed ID: 25352950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cold-inducible RNA-binding protein (Cirp) interacts with Dyrk1b/Mirk and promotes proliferation of immature male germ cells in mice.
    Masuda T; Itoh K; Higashitsuji H; Higashitsuji H; Nakazawa N; Sakurai T; Liu Y; Tokuchi H; Fujita T; Zhao Y; Nishiyama H; Tanaka T; Fukumoto M; Ikawa M; Okabe M; Fujita J
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10885-90. PubMed ID: 22711815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.